Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024)
Perspective Therapeutics' (CATX) quarterly Deferred Taxes came in at -$2.1 million in Q4 2024, down 126.72% year-over-year from $7.8 million in Q1 2024, and down 126.72% quarter-over-quarter from $7.8 million in Q4 2023.
Powered by 
Analysis
Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024) Analysis & Trends
Perspective Therapeutics has disclosed Deferred Taxes across 2 years of filings, most recently posting -$2.1 million for Q4 2024.
- In Q4 2024, Deferred Taxes fell 126.72% year-over-year to -$2.1 million; the TTM figure through Jun 2026 stood at -$2.1 million (changed 0.0% YoY), while the FY2025 annual figure was -$793000.0, up 62.18% from the prior year.
- Deferred Taxes came in at -$2.1 million for Q4 2024 at Perspective Therapeutics, down from $7.8 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $7.8 million in Q4 2023 to a low of -$10.5 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -291.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -587.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -69.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 194.40 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -27.60 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Mar 31, 2023 | -10.50 Mn |